State-of-the-Art Advances of Nanomedicine for Diagnosis and Treatment of Bladder Cancer

Kong, Chen-Fan; Zhang, Shaohua; Lei, Qifang; Wu, Song

doi:10.3390/bios12100796

Cited by 13 publications

(8 citation statements)

References 146 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Compared to systemic administration, intravesical administration has significant advantages, as it could achieve higher drug concentrations locally, enhance the killing effect on tumors, and avoid systemic exposure of drugs to reduce side effects . However, the production and excretion of urine result in a brief intravesical retention time of drugs, greatly limiting their therapeutic efficacy. , High amine and catechol(3,4-dihydroxybenzene) content endow PD NPs with strong adhesion .…”

Section: Resultsmentioning

confidence: 99%

Hyaluronic Acid-Conjugated Fluorescent Probe-Shielded Polydopamine Nanomedicines for Targeted Imaging and Chemotherapy of Bladder Cancer

Qiu,

Wang,

Zhi

et al. 2023

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

Bladder cancer is one of the most common malignancies in the urinary system, with high risk of recurrence and progression. However, the difficulty in detecting small tumor lesions and the lack of selectivity of intravesical treatment seriously affect the prognosis of patients with bladder cancer. In the present work, a nanoparticle-based delivery system with tumor targeting, high biocompatibility, simple preparation, and the ability to synergize imaging and therapy was fabricated. Specifically, this nanosystem consisted of the core of doxorubicin (DOX)-loaded polydopamine nanoparticles (PDD NPs) and the shell of hyaluronic acid (HA)-conjugated IR780 (HA-IR780). The HA-IR780-covered PDD NPs (HR-PDD NPs) demonstrated tumor targeting and visualization both in vitro and in vivo with properties of promoted cancer cell endocytosis and lysosomal escape, efficiently delivering drugs to the target site and exerting a killing effect on tumor cells. Encouragingly, intravesical instillation of HR-PDD NPs improved drug retention in the bladder and promoted its accumulation in tumor tissue, resulting in better tumor proliferation inhibition and apoptosis in an orthotopic bladder cancer model in rats. This study provides a promising strategy for the diagnosis and therapy of bladder cancer.

show abstract

Section: Resultsmentioning

confidence: 99%

Hyaluronic Acid-Conjugated Fluorescent Probe-Shielded Polydopamine Nanomedicines for Targeted Imaging and Chemotherapy of Bladder Cancer

Qiu,

Wang,

Zhi

et al. 2023

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

show abstract

“…Chemotherapy : Intravenous infusion chemotherapy constitutes the most effective technique for avoiding transurethral resection of BC and the prevention or postponement of disease progression 149 in patients whose malignancies cannot be eliminated or whose tumors possess great histopathological characteristics. Poor targeting ability, limited drug penetration, shorter recovery time, inconsistent action, and then the incapacity to slow down the release process are all issues that now plague intravesical chemotherapy because of the existence of the BPB (Figure 8).…”

Section: Using Nanomedicine For Bladder Cancer Therapymentioning

confidence: 99%

“…Multiple investigations have demonstrated the promising potential of using nanotechnology in the treatment of BC, and as a result, scientists are increasingly combining nanotechnology with traditional therapeutic approaches to address the various obstacles currently encountered when dealing with this disease. 3 Chemotherapy: Intravenous infusion chemotherapy constitutes the most effective technique for avoiding transurethral resection of BC and the prevention or postponement of disease progression 149 in patients whose malignancies cannot be eliminated or whose tumors possess great histopathological characteristics. Poor targeting ability, limited drug penetration, shorter recovery time, inconsistent action, and then the incapacity to slow down the release process are all issues that now plague intravesical chemotherapy because of the existence of the BPB (Figure 8).…”

Section: Using Nanomedicine For Bladder Cancer Therapymentioning

confidence: 99%

miRNAs involvement in the etiology and targeted therapy of bladder cancer: Interaction between signaling pathway

Sharma,

Malviya

2023

Precision Medical Sciences

View full text Add to dashboard Cite

Bladder cancer (BC) accounts for roughly 3% of all cancer diagnoses in developed countries. The prognosis could be improved significantly if the cancer is detected and classified as either muscle‐invasive bladder cancer (MIBC) or non‐muscle‐invasive bladder cancer (NMIBC) as promptly as possible. A potential ray of hope for the treatment of BC has emerged with the rapid development of nanomedicine and microRNAs (miRNAs), which promise to have fewer adverse effects, more tumor‐inhibitory effects, and decreased drug resistance. The complex interplay between hereditary and environmental variables is the root cause of this malignancy. Gene expression can be regulated by miRNAs, which are small, non‐coding RNAs that can either prevent the translation of protein‐coding genes or cleave RNA transcripts at certain locations. Elevated genomics has enabled a more extensive investigation of miRNAs whose expression is considerably different in BC patients compared to healthy volunteers or between BC tumor tissues and peripheral tissues. miRNAs have recently been discovered to be important regulators of BC cell carcinogenicity. Inaccurate diagnoses and prolonged treatment delays are more likely to occur due to the current diagnostic process such as lack of sensitivity and specificity and poor image quality. Patients now have access to a plethora of treatment options, including but not limited to surgery, chemotherapy, immunotherapy, gene therapy, and other innovative medicines, and in some cases, combination therapies. BC is one of the deadliest and most disabling malignancies affecting the urinary tract. Cancer of the urinary bladder has a terrible propensity for being fatal. BC is an intricate illness whose development can be affected by multiple parameters. Standard treatments for BC increase prognosis and survival, although recurrence is a major concern for patients. miRNAs are naturally occurring, small RNA molecules that have been linked to cancer through their expression being dysregulated. miRNAs modulate many cellular activities including proliferation, migration, differentiation, and apoptosis. MiRNA dysregulation is recognized in BC, and miRNAs are used as diagnostic and prognostic indicators. However, this manuscript discusses the recent progress made in nanomedicine and the function of miRNAs in the pathogenesis and targeted therapy of BC.

show abstract

“…Traditional treatments such as surgical resection, chemotherapy, and radiotherapy are generally used in clinical practice for UC. Although these methods can limit the progression of UC to a certain extent, the efficacy of these therapies is extremely limited for advanced and recurrent tumors, and patients have a low survival rate and poor prognosis ( Kong et al, 2022 ). Also, the extensive cell-killing mechanism of radiotherapy can cause serious adverse effects on patients and affect their survival and quality of life ( Ji et al, 2022 ).…”

Section: Introductionmentioning

confidence: 99%

The mechanism and clinical application of DNA damage repair inhibitors combined with immune checkpoint inhibitors in the treatment of urologic cancer

Xie¹,

Jiang²,

Wang³

et al. 2023

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Urologic cancers such as kidney, bladder, prostate, and uroepithelial cancers have recently become a considerable global health burden, and the response to immunotherapy is limited due to immune escape and immune resistance. Therefore, it is crucial to find appropriate and effective combination therapies to improve the sensitivity of patients to immunotherapy. DNA damage repair inhibitors can enhance the immunogenicity of tumor cells by increasing tumor mutational burden and neoantigen expression, activating immune-related signaling pathways, regulating PD-L1 expression, and reversing the immunosuppressive tumor microenvironment to activate the immune system and enhance the efficacy of immunotherapy. Based on promising experimental results from preclinical studies, many clinical trials combining DNA damage repair inhibitors (e.g., PARP inhibitors and ATR inhibitors) with immune checkpoint inhibitors (e.g., PD-1/PD-L1 inhibitors) are underway in patients with urologic cancers. Results from several clinical trials have shown that the combination of DNA damage repair inhibitors with immune checkpoint inhibitors can improve objective rates, progression-free survival, and overall survival (OS) in patients with urologic tumors, especially in patients with defective DNA damage repair genes or a high mutational load. In this review, we present the results of preclinical and clinical trials of different DNA damage repair inhibitors in combination with immune checkpoint inhibitors in urologic cancers and summarize the potential mechanism of action of the combination therapy. Finally, we also discuss the challenges of dose toxicity, biomarker selection, drug tolerance, drug interactions in the treatment of urologic tumors with this combination therapy and look into the future direction of this combination therapy.

show abstract

State-of-the-Art Advances of Nanomedicine for Diagnosis and Treatment of Bladder Cancer

Cited by 13 publications

References 146 publications

Hyaluronic Acid-Conjugated Fluorescent Probe-Shielded Polydopamine Nanomedicines for Targeted Imaging and Chemotherapy of Bladder Cancer

Hyaluronic Acid-Conjugated Fluorescent Probe-Shielded Polydopamine Nanomedicines for Targeted Imaging and Chemotherapy of Bladder Cancer

miRNAs involvement in the etiology and targeted therapy of bladder cancer: Interaction between signaling pathway

The mechanism and clinical application of DNA damage repair inhibitors combined with immune checkpoint inhibitors in the treatment of urologic cancer

Contact Info

Product

Resources

About